Hot Life Science Investor Mandate 4: Corporate VC Invests in Preclinical & Clinical-Stage Orphan Drugs

7 Jan

A strategic investment company formed by a pharma firm makes investments ranging from $3 million to $20 million acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and has filed (or will file) a US IND.

The firm invests in therapeutics, and in this sector the firm is interested in both early stage, preclinical assets and companies with assets in the clinic. The firm will consider any type of therapeutic technology (including small molecules, large molecules and gene therapies), and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases, CNS diseases and primary care indications (such as influenza) will not be considered. Drug-device combinations will also be considered.

The firm prefers to work with companies who have opened dialogue with the FDA. The firm considers a high-quality management team to be a significant requirement of their investment criteria. It is preferred that assets can reach the marketplace 3-5 years post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: